References
- Xiao J, Gao L, Zhang M, et al. Clinical features of diffuse leptomeningeal glioneuronal tumor with rapid blindness misdiagnosed as NMOSD and literature review. SN Compr Clin Med. 2019;1(6):434–441.
- Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820.
- Deng MY, Sill M, Chiang J, et al. Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathol. 2018;136(2):239–253.
- Kak M, Nanda R, Ramsdale EE, et al. Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities. J Clin Neurosci. 2015;22(4):632–637.
- Nambirajan A, Suri V, Kedia S, et al. Paediatric diffuse leptomeningeal tumor with glial and neuronal differentiation harbouring chromosome 1p/19q co-deletion and H3. 3 K27M mutation: unusual molecular profile and its therapeutic implications. Brain tumor Pathol. 2018;35(3):186–191.
- Hardiman O, Berg L. Edaravone: a new treatment for ALS on the horizon? Lancet Neurol. 2017;16(7):490–491.
- Wen XR, Tang M, Qi DS, et al. Butylphthalide suppresses neuronal cells apoptosis and inhibits JNK–caspase3 signaling pathway after brain ischemia/reperfusion in rats. Cell Mol Neurobiol. 2016;36(7):1087–1095.
- Lim M, Kurian M, Penn A, et al. Visual failure without headache in idiopathic intracranial hypertension. Arch Dis Child. 2005;90(2):206–210.
- Baheti NN, Nair M, Thomas SV. Long-term visual outcome in idiopathic intracranial hypertension. Ann Indian Acad Neurol. 2011;14(1):19.
- Zhang LF, Hargens AR. Spaceflight-induced intracranial hypertension and visual impairment: pathophysiology and countermeasures. Physiol Rev. 2018;98(1):59–87.